HomeBUSINESS
BUSINESS

Lenvima Stalls QOL Lowering in HCC Patients: Eisai
(Sep.12.2017)

Eisai said on September 11 that its anticancer agent Lenvima (lenvatinib) delayed the deterioration in quality of life (QOL) compared to sorafenib in patients with hepatocellular carcinoma (HCC) ...
(LOG IN FOR FULL STORY)

News Calendar